AcelRx Marches Onward With NDA Filing For Pain Drug-Device
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharma is planning to file an NDA for its sublingual sufentanil NanoTab system for pain in the third quarter after the first of two pivotal trials reads out positively.